Top

Journal of Assisted Reproduction and Genetics

Published in:

01-07-2015 | Case Report

Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition

Authors: Samuel Santos-Ribeiro, Nikolaos P. Polyzos, Katrien Stouffs, Michel De Vos, Sara Seneca, Herman Tournaye, Christophe Blockeel

Published in: Journal of Assisted Reproduction and Genetics | Issue 7/2015

Abstract

Purpose

We report on the results of the whole-genome analysis performed in a patient who developed severe ovarian hyperstimulation syndrome (OHSS) following gonadotropin-releasing hormone (GnRH) agonist triggering in a “freeze-all” protocol.

Methods

A 30-year-old patient with polycystic ovary syndrome who developed severe early-onset OHSS with clinical ascites, and slight renal and hepatic dysfunction was admitted for monitoring and treatment with cabergoline and intravenous albumin. Exome sequencing to assess for any known genetic predisposition for OHSS was performed.

Results

No known genetic variants associated with OHSS predisposition were found.

Conclusions

Case reports of severe OHSS following a “freeze-all” strategy are starting to arise, showing that OHSS has not been completely eliminated with this approach. Further studies should be conducted to confirm if such cases may be due to genetic predisposition or not.

Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85(1):112–20. doi:10.1016/j.fertnstert.2005.07.1292.PubMedCrossRef

Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73(5):901–7.PubMedCrossRef

Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84–91. doi:10.1016/j.fertnstert.2007.02.002.PubMedCrossRef

Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006;86(6):1682–7. doi:10.1016/j.fertnstert.2006.05.049.PubMedCrossRef

Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003;9(1):77–96.PubMedCrossRef

Vloeberghs V, Peeraer K, Pexsters A, D’Hooghe T. Ovarian hyperstimulation syndrome and complications of ART. Best Pract Res Clin Obstet Gynaecol. 2009;23(5):691–709. doi:10.1016/j.bpobgyn.2009.02.006.PubMedCrossRef

Humaidan P, Kol S, Papanikolaou EG. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011;17(4):510–24. doi:10.1093/humupd/dmr008.PubMedCrossRef

Engmann L, Benadiva C. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. Fertil Steril. 2012;97(3):531–3. doi:10.1016/j.fertnstert.2011.12.020.PubMedCrossRef

Garcia-Velasco JA. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertil Steril. 2012;97(3):527–8. doi:10.1016/j.fertnstert.2011.12.010.PubMedCrossRef

10.

Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12(2):159–68. doi:10.1093/humupd/dmi045.PubMedCrossRef

11.

Herrero L, Pareja S, Losada C, Cobo AC, Pellicer A, Garcia-Velasco JA. Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome. Fertil Steril. 2011;95(3):1137–40. doi:10.1016/j.fertnstert.2010.09.040.PubMedCrossRef

12.

Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod. 2013;28(9):2529–36. doi:10.1093/humrep/det304.PubMedCrossRef

13.

Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online. 2009;19(4):486–92. doi:10.1016/j.rbmo.2009.06.001.PubMedCrossRef

14.

Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod. 2011;26(10):2593–7. doi:10.1093/humrep/der251.PubMedCrossRef

15.

Bodri D, Guillén JJ, Trullenque M, Schwenn K, Esteve C, Coll O. Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. Fertil Steril. 2010;93(7):2418–20. doi:10.1016/j.fertnstert.2009.08.036.PubMedCrossRef

16.

Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril. 2011;95(6):2029–33. doi:10.1016/j.fertnstert.2011.01.163.

17.

Ling LP, Phoon JW, Lau MS, Chan JK, Viardot-Foucault V, Tan TY, et al. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at ‘freeze-all strategy’. Reprod Biomed Online. 2014;29(3):392–4. doi:10.1016/j.rbmo.2014.05.012.PubMedCrossRef

18.

Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online. 2014. doi:10.1016/j.rbmo.2014.07.022.PubMed

19.

Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101(4):1008–11. doi:10.1016/j.fertnstert.2014.01.019.PubMedCrossRef

20.

Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44(6):430–40.PubMedCrossRef

21.

Kol S. A case of severe early-onset OHSS after GnRH-agonist triggering. Fertil Steril. 2011;96(3):e151. doi:10.1016/j.fertnstert.2011.06.057. author reply e152.PubMedCrossRef

22.

Abu-Louz SK, Ahmed AA, Swan RW. Spontaneous ovarian hyperstimulation syndrome with pregnancy. Am J Obstet Gynecol. 1997;177(2):476–7.PubMedCrossRef

23.

Ayhan A, Tuncer ZS, Aksu AT. Ovarian hyperstimulation syndrome associated with spontaneous pregnancy. Hum Reprod. 1996;11(8):1600–1.PubMedCrossRef

24.

Di Carlo C, Bruno P, Cirillo D, Morgera R, Pellicano M, Nappi C. Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome. Hum Reprod. 1997;12(10):2115–7.PubMedCrossRef

25.

group E-A-sPcw. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.CrossRef

26.

Altmae S, Hovatta O, Stavreus-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update. 2011;17(6):813–28. doi:10.1093/humupd/dmr034.PubMedCrossRef

27.

Moron FJ, de Castro F, Royo JL, Montoro L, Mira E, Saez ME, et al. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenet Genomics. 2006;16(7):485–95. doi:10.1097/01.fpc.0000215073.44589.96.PubMedCrossRef

28.

Rizk B. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2009;19(1):14–27.PubMedCrossRef

29.

O’Brien TJ, Kalmin MM, Harralson AF, Clark AM, Gindoff I, Simmens SJ, et al. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. Reprod Biol Endocrinol RB&E. 2013;11(1):71. doi:10.1186/1477-7827-11-71.CrossRef

30.

Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD. Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. Fertil Steril. 2009;91(2):432–9. doi:10.1016/j.fertnstert.2007.11.093.PubMedCrossRef

31.

Daelemans C, Smits G, de Maertelaer V, Costagliola S, Englert Y, Vassart G, et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab. 2004;89(12):6310–5. doi:10.1210/jc.2004-1044.PubMedCrossRef

32.

Dulitzky M, Cohen SB, Inbal A, Seidman DS, Soriano D, Lidor A, et al. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. Fertil Steril. 2002;77(3):463–7.PubMedCrossRef

33.

Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308–11.PubMedCentralPubMedCrossRef

34.

Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812–4. doi:10.1093/nar/gkg509.PubMedCentralPubMedCrossRef

35.

Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9. doi:10.1038/nmeth0410-248.PubMedCentralPubMedCrossRef

36.

Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;5:CD001750. doi:10.1002/14651858.CD001750.pub3.PubMed

37.

Humaidan P. Agonist trigger: what is the best approach? Agonist trigger and low dose hCG. Fertil Steril. 2012;97(3):529–30. doi:10.1016/j.fertnstert.2011.11.016.PubMedCrossRef

38.

Griesinger G, von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod. 2007;22(5):1348–52. doi:10.1093/humrep/dem006.PubMedCrossRef

39.

Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod. 2013;28(9):2522–8. doi:10.1093/humrep/det124.PubMedCrossRef

Title: Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition
Authors: Samuel Santos-Ribeiro
Nikolaos P. Polyzos
Katrien Stouffs
Michel De Vos
Sara Seneca
Herman Tournaye
Christophe Blockeel
Publication date: 01-07-2015
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 7/2015
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-015-0498-y

At a glance: The STEP trials

Springer Medicine

Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2015

Quality control in the ART laboratory: matters arising

Morphokinetic parameters using time-lapse technology and day 5 embryo quality: a prospective cohort study

Preconception counseling: do patients learn about genetics from their obstetrician gynecologists?

Letter to the editor

High mobility group box 1 protein polymorphism affects susceptibility to recurrent pregnancy loss by up-regulating gene expression in chorionic villi

Increased DNA damage and repair deficiency in granulosa cells are associated with ovarian aging in rhesus monkey